万赛维治疗CMV视网膜炎疗效如何呢?
(Valganciclovir) is mainly used to treat cytomegalovirus retinitis. It is available in a variety of clinical dosage forms. Patients should consult a doctor before taking the medicine and use the medicine according to the doctor's judgment. The recommended dose in adults with normal renal function, for the treatment of induction of cytomegalovirus retinitis: The recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Maintenance: After induction therapy, or in adult patients with inactive cytomegalovirus retinitis, the recommended dose is 900 mg orally once daily.
Clinical studies of Valganciclovir in AIDS patients infected with CMV retinitis have shown that Valganciclovir tablets and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Vancevir tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week four was the same in both groups.
After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Vancevir tablets at a dose of 900 mg per day. Among patients who received Vancevir tablets or intravenous ganciclovir induction therapy followed by Vancevir tablets maintenance therapy, the mean (median) time from randomization to progression of CMV retinitis was: 226 (160) days and 219 (125) days.
The clinical antiviral effect of the tablet has been demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After four weeks of treatment with Vancevir tablets, the detection rate of CMV virus decreased from 46% (32/69) at study enrollment to 7% (4/55). Monitoring of complete blood count and platelet count is recommended during treatment. For patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, it is recommended to use blood cell growth factor therapy and/or consider suspending medication.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)